WO2009095210A1 - Composition comprenant un antiacide et des antagonistes h2 - Google Patents

Composition comprenant un antiacide et des antagonistes h2 Download PDF

Info

Publication number
WO2009095210A1
WO2009095210A1 PCT/EP2009/000523 EP2009000523W WO2009095210A1 WO 2009095210 A1 WO2009095210 A1 WO 2009095210A1 EP 2009000523 W EP2009000523 W EP 2009000523W WO 2009095210 A1 WO2009095210 A1 WO 2009095210A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
antagonist
antacid
granulate
aluminium
Prior art date
Application number
PCT/EP2009/000523
Other languages
English (en)
Inventor
Shivaji Purwar
Original Assignee
Bayer Consumer Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care Ag filed Critical Bayer Consumer Care Ag
Publication of WO2009095210A1 publication Critical patent/WO2009095210A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • composition Comprising an Antacid and a H2-antagonists
  • the present invention relates to a stable solid composition comprising an antacid and a H2- antagonist without unpleasant or bitter taste, its process for preparation and its use for treating and preventing gastric disorders.
  • H2-antagonists e.g. ranitidine, cimetidine or famotidine
  • ranitidine e.g. ranitidine
  • cimetidine e.g. famotidine
  • their slow onset of action is unlikely to meet the consumer requirement for rapid relief.
  • Antacids e.g. aluminium hydroxide, magnesium hydroxide or hydrotalcite
  • They are described for providing rapid relief from the symptoms of excess of stomach acid by neutralizing the acid. They can be used for the treatment of heartburn, gastritis and other gastric disorders.
  • a combination of both ingredients is desirable in terms of rapid relief of heartburn affected by the antacid combined with a long lasting effect affected by the H2-antagonist.
  • EP 0 286 781 describes in example 2 a tablet comprising ranitidine as H2-antagonist, aluminium hydroxide and calciumcarbonat as antacid and in addition caramel flavour to domineer the unpleasant taste of ranitidine.
  • the tablets are prepared by dry mixing of the ingredients and compressing to tablets. Data on stability are not disclosed.
  • WO 92/00102 and WO 93/12779 describe tablets comprising cimetidine, ranitidine or famotidine as H2-antagonists, aluminium hydroxide and magnesium hydroxide or sodium bicarbonate as antacids and in addition palatability aids such as flavours and icing sugar as coating for taste masking purposes. Data on stability are not disclosed.
  • EP 1 019 066 describes chewable tablets comprising coated famotidine granules and calcium carbonate and magnesium hydroxide as antacid.
  • the coated famotidine granules are prepared by dry rotogranulation including a coating.
  • the coating of the famotidine prohibits a unpleasant or bitter taste. Data on stability are not disclosed.
  • EP 0 600 725 describes tablets comprising coated famotidine granules and antacids wherein the famotidine granules and the antacid are in different layers separated by a impermeable barrier for stability reasons.
  • the coated famotidine granules are prepared by dry rotogranulation including a coating.
  • the coating of the famotidine prohibits a unpleasant or bitter taste and the barrier prohibits the interaction of both ingredients.
  • US 6,090,412 describes chewable tablets containing cimetidine, famotidine or ranitidine as H2 antagonists and magnesium hydroxide and aluminium hydroxide as antacids wherein at least parts of the antacids are used as coated granules.
  • the problem to be solved was, providing an alternative stable solid dosage form containing a H2- antagonist and an antacid having no unpleasant taste.
  • a solid dosage form comprising a H2-antagonist and an antacid wherein the H2-antagonist is used in the form of granules obtainable by wet granulation wherein the wet granulation process comprises the steps of spraying of a suspension comprising the H2-antagonist and at least one or more first hydrophilic polymeric substances to at least one or more second polymeric substances in dry form and perform the granulation by mixing.
  • H2-antagonists are well known and include, but are not limited to, famotidine, ranitidine, cimetidine, nizatidine and mixtures thereof. Preference is given to famotidine.
  • Antacids include, but are not limited to, magnesium hydroxide, magnesium carbonate, calcium carbonate, aluminium hydroxide, aluminium carbonate, aluminium phosphate, aluminium hydroxyl carbonate, dihydroxy aluminium sodium carbonate, aluminium magnesium glycinate, dihydroxy aluminium aminoacetate, dihydroxy aluminium aminoacetic acid, bismuth aluminate, bismuth carbonate, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, calcium phosphate, hydrated magnesium aluminate, magnesium aluminium silicates, magnesium glycinate, magnesium oxide, magnesium trisilicate, sodium bicarbonate, hydrotalcite and mixtures thereof. Preference is given to hydtrotalcite , calcium carbonat, magnesium hydroxide and magnesium carbonate, hi particular hydrotalcite is used as antacid.
  • the amount of H2-antagonist in the composition according to the invention is from 1 to 500 mg, preferably from 5 to 100 mg.
  • Preferred amounts of famotidine in the composition is from 5 to 50 mg, preferably from 5 to 20 mg, more preferably 10 mg.
  • a suitable amount of cimetidine in the composition is from 1 to 50 mg, preferably 1 to 25 mg, more preferably 1 to 10 mg.
  • Preferred amounts of ranitidine in the composition are from 1 to 50 mg, preferably 1 to 25, more preferably 1 to 25, most preferably 1 to 5 mg.
  • the amount of the antacid, preferably hydrotalcite, in the composition is from 100 to 2000 mg, preferably from 350 to 1500 mg, more preferably from 500 to 1100 mg.
  • the first hydrophilic polymeric substances include, but are not limited to, polyvinylic alcohol, hypromellose (hydroxypropylrnethylcellulose or HPMC), starch, starch derivatives, pregelatinized starch, cellulose derivatives, microcrystalline cellulose, croscarmellose (carboxymethylcellulose), sodium carboxymethylcellulose, polyvinylpyrrolidon (PVP) and crosslinked polyvinylpyrrolidon.
  • a first hydrophilic polymeric substance selected from the group consisting of hypromellose (hydroxypropylmethylcellulose or HPMC), pregelatinized starch, microcrystalline cellulose and croscarmellose (carboxymethylcellulose). Most preferably the first hydrophilic polymeric substance is hypromellose (hydroxypropylmethylcellulose or HPMC).
  • the amount of the first hydrophilic polymeric substance or substances is from 0.1 to 5 %, preferably from 0.3 to 2 %, more preferably from 0.5 to 1 % by weight of the total composition.
  • the second polymeric substances include, but are not limited to, hypromellose (hydroxypropylmethylcellulose or HPMC), starch, starch derivatives, pregelatinized starch, cellulose derivatives, microcrystalline cellulose, croscarmellose (carboxymethylcellulose), sodium carboxymethylcellulose, polyvinylpyrrolidon (PVP) and crosslinked polyvinylpyrrolidon.
  • HPMC hypromellose
  • starch starch derivatives
  • pregelatinized starch cellulose derivatives
  • microcrystalline cellulose microcrystalline cellulose
  • croscarmellose carboxymethylcellulose
  • PVP polyvinylpyrrolidon
  • crosslinked polyvinylpyrrolidon crosslinked polyvinylpyrrolidon.
  • the amount of the second polymeric substance or substances is from 1 to 20 %, preferably from 7 to 15 %, more preferably from 8 to 12 % by weight of the total composition.
  • the composition according to the invention is administered orally one or more, preferably up to three, more preferably up to two times per day. With each administration the number of dosage forms taken in at the same time should not exceed two.
  • composition according to the present invention can be used for treating or preventing gastric disorders e.g. acid indigestion, heartburn, hyperacidity and gastritis, preferably acute gastritis, in a patient.
  • gastric disorders e.g. acid indigestion, heartburn, hyperacidity and gastritis, preferably acute gastritis
  • a patient for the purpose of this invention, is a mammal, including a human.
  • Subject of the present invention is a stable and solid oral composition comprising a H2-antagonist and an antacid having no unpleasant or bitter taste.
  • H2- antagonists Normally several provisions have to be met to provide a stable composition comprising a H2- antagonist and an antacid having no bitter or unpleasant taste.
  • Compounds which are H2- antagonists are normally characterized by their unpleasant and/or bitter taste, so that a complex and expensive taste masking technology is needed to mask the taste of the H2-antagonist.
  • hi addition H2-antagonists and antacids comprised in one formulation can cause stability problems.
  • a solid composition comprising a H2-antagonist and an antacid
  • the composition is made of a first granulate comprising the H2-antagonist produced by wet granulation and of a second granulate comprising the antacid
  • the wet granulation process of the first granulate comprises the steps of spraying of a suspension comprising the H2-antagonist and at least one or more first hydrophilic polymeric substance to at least one or more second polymeric substances in dry form and perform the granulation by mixing.
  • a solid composition comprising a H2-antagonist and an antacid
  • the composition is made of a first granulate comprising the H2-antagonist but no antacid produced by wet granulation and of a second granulate comprising the antacid but no H2-antagonist
  • the wet granulation process of the first granulate comprises the steps of spraying of a suspension comprising the H2-antagonist and at least one or more first hydrophilic polymeric substance to at least one or more second polymeric substances in dry form and perform the granulation by mixing.
  • the solvent can be water or alcohol such as ethanol or a mixture thereof.
  • composition of the present invention is that for the preparation of the composition a complex and expensive taste masking technology known in the prior art such as coating of tablets or coating of granules or putting one or more of the ingredients into a capsule is not needed.
  • the composition of the present invention can be prepared by simple and well-known standard procedures.
  • Another well-known taste masking method is the addition of flavours in order to cover and mask the unpleasant taste. This kind of taste masking is normally restricted to only a few applicable flavours which have to be selected in each case.
  • flavouring ingredients are not needed for taste masking in the composition of the present invention.
  • composition of the present invention is also that a particular technology in order to guarantee a high stability, such as coating technologies, multilayer tablets, tablets containing barriers, are not needed.
  • Subject of the present invention is a stable and solid oral composition
  • a H2-antagonist and an antacid which has no unpleasant or bitter taste and which is not a coated tablet, coated granule, multilayered tablet or capsule but consists of a single matrix.
  • the composition according to the invention is characterized by a high stability.
  • composition according to the invention comprises suitable administration forms which deliver the compounds of the invention and which include, but are not limited to, solid formulations such as tablets, tablets which disintegrate rapidly in the oral cavity (orodispersible tablets), powders, sachets, granules, pellets, chewable tablets, and dispersible tablets.
  • solid formulations such as tablets, tablets which disintegrate rapidly in the oral cavity (orodispersible tablets), powders, sachets, granules, pellets, chewable tablets, and dispersible tablets.
  • ingredients of the oral dosage forms are those which are accepted for pharmaceuticals and nutritional supplements and physiologically unobjectionable, for example: as fillers cellulose derivatives (e.g. microcrystalline cellulose), sugars (e.g. lactose), sugar alcohols (e.g. mannitol, sorbitol), inorganic fillers (e.g. calcium phosphates), binders (e.g. polyvinylpyrrolidone, gelatin, starch derivatives and cellulose derivatives), and all other excipients required to produce formulations of pharmaceuticals and nutritional supplements of the desired properties, e.g. lubricants (magnesium stearate), e.g. disintegrants (e.g.
  • lubricants magnesium stearate
  • disintegrants e.g.
  • crosslinked polyvinylpyrrolidone, sodium carboxymethylcellulose e.g. wetting agents (e.g. sodium lauryl sulphate), e.g. release-slowing agents (e.g. cellulose derivatives, polyacrylic acid derivatives), e.g. stabilizers, e.g. antioxidants, e.g. preservatives, e.g. coloured pigments.
  • wetting agents e.g. sodium lauryl sulphate
  • release-slowing agents e.g. cellulose derivatives, polyacrylic acid derivatives
  • stabilizers e.g. antioxidants, e.g. preservatives, e.g. coloured pigments.
  • composition according to the present invention involves three steps: i) wet granulation of the H2-antagonist, ii) granulation of the antacid, iii) mixing of the granulates of i) and ii) to the final blend and optionally compression into tablets.
  • Solvent preferably water, more preferably water having a temperature of 5 to 10 0 C, is added to the suspension until a clear solutions is formed.
  • the solution is brought to room temperature and the H2-antagonist, preferably famotidine, is added to form a suspension.
  • a second mixer at least one or more second polymeric substances in dry form are blended. Wet granulation is performed by spraying the H2- antagonist containing suspension into the blend while mixing.
  • the wet granulate is optionally screened through a screen with a pore size from 5 to 15 mesh, preferably 10 to 15 mesh.
  • the wet granulate is dried by e.g. a fluid bed dryer and optionally screened through a screen with a pore size of 25 to 35 mesh, preferably 20 to 30 mesh (i.e. 600 to 800 ⁇ m) to give the final H2-antagonist granulate.
  • the amount of the first hydrophilic polymeric substance or substances in the granulate containing the H2-antagonist is from 1 to 20 %, preferably from 5 to 15 %, more preferably from 10 to 13 % by weight of the total famotidine granulate.
  • the amount of the second polymeric substance or substances in the granulate containing the H2- antagonist is from 50 to 90 %, preferably from 65 to 85 %, more preferably from 70 to 82 % by weight of the total famotidine granulate.
  • Step ii): The granulate comprising the antacid can be prepared by standard granulation technology.
  • the antacid preferably hydrotalcite, more preferably very fine hydrotalcite and free flowing hydrotalcite, pregelatinized starch, microcrystalline cellulose, croscarmellose and silicon dioxide are blended for e.g.
  • the antacid preferably hydrotalicte, more preferably very fine hydrotalcite and free flowing hydrotalcite, pregelatinized starch, microcrystalline cellulose, croscarmellose are screened through a screen with a pore size of 10 to 20 mesh, preferably 16 mesh, and the silicon dioxide is screened through a screen with a pore size of 25 to 35 mesh, preferably 30 mesh.
  • Magnesium stearate is added and the blend is mixed for e.g. 3 minutes. The blend is roller compacted to form the final antacid granulate.
  • Step iii): The H2-antagonist granulate of step i) and the antacid granulate of step ii) are mixed together with optionally further antacid, preferably hydrotalcite, more preferably free flowing hydrotalcite, and croscarmellose sodium.
  • optionally further antacid preferably hydrotalcite, more preferably free flowing hydrotalcite, and croscarmellose sodium.
  • optionally further ingredients/excipients are added.
  • Magnesium stearate is added which is optionally previously screened through a screen with a pore size of 25 to 35 mesh, preferably 30 mesh. After mixing for e.g. 3 minutes the final blend is formed.
  • the final blend can be compressed into tablets.
  • step i) and ii) are mixed together with the granulates of step i) and ii) for about 10 minutes.
  • Magnesium stearate is added and mixed for further 3 minutes. Finally the blend is compressed into chewable tablets.
  • Formulations 1 to 3 are examples for swallowable tablets:
  • Example 2 Manufacturing process for swallowable tablets of example 1
  • Hypromellose is suspended by mixing in a portion of water pre-heated to a temperature from 80 to 90 0 C. Cold water having a temperature of 5 to 10 0 C is added to the suspension until a clear solutions is formed. The solution is brought to room temperature and famotidine is added to form a suspension. In a second mixer pregelatinized starch, microcrystalline cellulose and croscarmellose is blended. The H2-antagonist containing suspension is sprayed into the blend while mixing and the wet granulation is performed. The wet granulate is screened through a screen with a pore size of 10 mesh. The wet granulate is dried by a fluid bed dryer and screened through a screen with a pore size of 30 mesh to give the final famotidine granulate.
  • Very fine hydrotalcite and free flowing hydrotalcite, pregelatinized starch, microcrystalline cellulose, croscarmellose and silicon dioxide are blended for 15 minutes wherein the very fine hydrotalcite, the free flowing hydrotalcite, pregelatinized starch, microcrystalline cellulose, croscarmellose are screened through a screen with a pore size of 16 mesh, and the silicon dioxide is screened through a screen with a pore size of 30 mesh.
  • Magnesium stearate screened through a screen with a pore size of 30 mesh is added and the blend is mix for 3 minutes. The blend is roller compacted to form the final antacid granulate.
  • the famotidine granulate of step i) and the antacid granulate of step ii) are mixed together with free flowing hydrotalcite and croscarmellose sodium.
  • Magnesium stearate is added which is optionally previously screened through a screen with a pore size of 30 mesh. After mixing for 3 minutes the final blend is formed and can be compressed into swallowable tablets.
  • the 3 month accelerated stability data at 40°C and 75% room humidity determines the degradation of famotidine and shows for the formulations 1 and 2 of example 1 a high stability (remaining famotidine content in both formulations is 9.3 mg) in contrary to a regular formulation where the ingredients are only mixed together and then compressed (the amount of total impurities is 27.9% by weight of the total composition).
  • Formulations 4 to 6 are examples for chewable tablets:
  • Example 5 Manufacturing process for chewable tablets of example 4.
  • Step i) and ii) are identical to those described in example 2.
  • Free flowing hydrotalicte and xylitol are screened previously by a screen with screen of a pore size of 18 mesh and are mixed together with the granulates of step i) and ii) for about 10 minutes.
  • Magnesium stearate screend with a screen havin a pore size of 30 mesh is added and mixed for further 3 minutes. Finally the blend is compress into chewable tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur une composition solide stable comprenant un antiacide et un antagoniste H2 sans goût déplaisant ou amer, sur son procédé de préparation et sur son utilisation pour le traitement et la prévention de troubles gastriques.
PCT/EP2009/000523 2008-01-31 2009-01-28 Composition comprenant un antiacide et des antagonistes h2 WO2009095210A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1205108A 2008-01-31 2008-01-31
US12/012,051 2008-01-31

Publications (1)

Publication Number Publication Date
WO2009095210A1 true WO2009095210A1 (fr) 2009-08-06

Family

ID=40591951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/000523 WO2009095210A1 (fr) 2008-01-31 2009-01-28 Composition comprenant un antiacide et des antagonistes h2

Country Status (1)

Country Link
WO (1) WO2009095210A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101904865A (zh) * 2010-07-23 2010-12-08 湖北丽益医药科技有限公司 铝碳酸镁分散片及其制备方法
CN102961460A (zh) * 2012-12-10 2013-03-13 哈药集团三精制药股份有限公司 一种复方铝酸铋片的制备方法
CN104095875A (zh) * 2014-08-04 2014-10-15 烟台荣昌制药股份有限公司 法莫替丁钙镁咀嚼片
CN104906128A (zh) * 2015-06-04 2015-09-16 烟台荣昌制药股份有限公司 复方法莫替丁钙镁咀嚼片和制法
CN112294841A (zh) * 2020-10-21 2021-02-02 北京鑫开元医药科技有限公司 一种法莫替丁枸橼酸铋钾复方组合物、制备方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169640A (en) * 1987-05-08 1992-12-08 Smith Kline & French Laboratories, Ltd. Pharmaceutical compositions
EP0600725A1 (fr) * 1992-12-01 1994-06-08 McNEIL-PPC, INC. Compositions pharmaceutiques contenant un guanidinothiazole et des antiacides
EP0715846A1 (fr) * 1994-12-10 1996-06-12 Rhone-Poulenc Rorer Gmbh Composition pharmaceutique pour administration orale contenant des aminoacides
US5922351A (en) * 1991-03-27 1999-07-13 Bayer Corporation Lubricants for use in tabletting

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169640A (en) * 1987-05-08 1992-12-08 Smith Kline & French Laboratories, Ltd. Pharmaceutical compositions
US5922351A (en) * 1991-03-27 1999-07-13 Bayer Corporation Lubricants for use in tabletting
EP0600725A1 (fr) * 1992-12-01 1994-06-08 McNEIL-PPC, INC. Compositions pharmaceutiques contenant un guanidinothiazole et des antiacides
EP0715846A1 (fr) * 1994-12-10 1996-06-12 Rhone-Poulenc Rorer Gmbh Composition pharmaceutique pour administration orale contenant des aminoacides

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101904865A (zh) * 2010-07-23 2010-12-08 湖北丽益医药科技有限公司 铝碳酸镁分散片及其制备方法
CN102961460A (zh) * 2012-12-10 2013-03-13 哈药集团三精制药股份有限公司 一种复方铝酸铋片的制备方法
CN104095875A (zh) * 2014-08-04 2014-10-15 烟台荣昌制药股份有限公司 法莫替丁钙镁咀嚼片
CN104095875B (zh) * 2014-08-04 2016-06-29 烟台荣昌制药股份有限公司 法莫替丁钙镁咀嚼片
CN104906128A (zh) * 2015-06-04 2015-09-16 烟台荣昌制药股份有限公司 复方法莫替丁钙镁咀嚼片和制法
CN104906128B (zh) * 2015-06-04 2017-08-11 烟台荣昌制药股份有限公司 复方法莫替丁钙镁咀嚼片和制法
CN112294841A (zh) * 2020-10-21 2021-02-02 北京鑫开元医药科技有限公司 一种法莫替丁枸橼酸铋钾复方组合物、制备方法及其应用

Similar Documents

Publication Publication Date Title
US11013762B1 (en) Pharmaceutical compositions
US5169640A (en) Pharmaceutical compositions
EP1145711B1 (fr) Forme de dosage orale très fondante
RU2301662C2 (ru) Фармацевтический препарат, содержащий ингибитор протонной помпы и антациды
AU2005249175B2 (en) Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
US5989588A (en) Methods and compositions for preventing and treating heartburn
US5275823A (en) Pharmaceutical compositions
KR101653690B1 (ko) 제산제로서 사용되는 혼합 금속 화합물
AU620866B2 (en) Pharmaceutical compositions
CZ294084B6 (cs) Sypká granulovaná kompoziceŹ způsob její výroby a protipěnivá orální pevná dávková forma simethikonu
WO2009095210A1 (fr) Composition comprenant un antiacide et des antagonistes h2
EP1140013B1 (fr) Comprimes antiacides generant des suspensions moussantes
PL210931B1 (pl) Kompozycja w postaci stałej nadająca się do połykania zawierająca alginian, wodorowęglan i/lub węglan, jej zastosowanie oraz sposób wytwarzania
EP2389070B1 (fr) Formulations désintégrables de carbonate de lanthanum
CA3204079A1 (fr) Particule multicouche comprenant de la simethicone
CN117580567A (zh) 包含法莫替丁的药物组合物
CN116887816A (zh) 包含西甲硅油的多层颗粒
CA2267503C (fr) Procedes et compositions pour la prevention et le traitement des brulures d'estomac
AU2022244333A1 (en) A pharmaceutical composition comprising famotidine
JP2023163350A (ja) チュアブル錠又は口腔内崩壊錠
EA047703B1 (ru) Многослойные частицы, содержащие симетикон
WO1995033469A1 (fr) Antiacide solide et procede de production de ce compose
SK40596A3 (en) A pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09705216

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09705216

Country of ref document: EP

Kind code of ref document: A1